Makower is the Yock family professor of medicine and bioengineering at the Stanford Schools of Medicine and Engineering, and the Byers family director and co-founder of the Stanford Mussallem Center ...

ROYAL OAK, Mich. – It was a moment of pure joy, 15 years in the making. When Marie Hindee of Shelby Township saw the results of her first scan after undergoing a cutting edge new therapy for her blood ...

A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests. The anti-seizure medication, levetiracetam, was first approved ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

China is already dominating global electric vehicle battery sales, with CATL and BYD accounting for over 55% of the market alone last year. To promote safer, more efficient, higher-energy-density ...

Larimar Therapeutics (LRMR) added ~38% in the premarket on Tuesday after the rare disease drug developer said that the U.S. FDA has granted Breakthrough Therapy Designation for its lead compound, ...

Pokémon celebrates its 30th birthday this week and, as part of the celebrations, the brand has just revealed an astonishing 1025 variations of its 30th anniversary logo. Each design features a ...

James Ratcliff joined GameRant in 2022 as a Gaming News Writer. In 2023, James was offered a chance to become an occasional feature writer for different games and then a Senior Author in 2025. He is a ...

Mathematicians just made a big leap forward on one of the field’s all-time favorite problems. Curves—squiggly lines through space, such as a comet’s trajectory or a stock market trend—are some of math ...

Pokémon turns 30 this year, and The Pokémon Company is celebrating that milestone in all number of ways, including creating a special 30th anniversary logo for every individual Pokémon. That's right, ...

Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitable yet. CRISPR Therapeutics has a deep pipeline of ...